Artivion Inc. (AORT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Artivion Inc. (AORT) Healthcare & Pipeline Overview

Artivion, Inc. (AORT) is a medical device company focused on surgical solutions for cardiac and vascular diseases, offering a range of implantable tissues and devices. With a global presence and a history of innovation, Artivion competes in the medical device industry, marked by technological advancements and stringent regulatory requirements.

What Is the Investment Thesis for AORT?

Artivion presents a compelling investment thesis based on its established market position, diverse product portfolio, and growth opportunities in the medical device industry. With a market capitalization of $1.36B and a P/E ratio of 32.6, Artivion demonstrates financial stability and growth potential. The company's gross margin of 63.6% reflects its ability to maintain profitability while investing in research and development. Key growth catalysts include the expansion of its product lines, strategic acquisitions, and increasing demand for minimally invasive surgical procedures. However, investors may want to evaluate the potential risks associated with regulatory approvals, competition, and fluctuating free cash flow, which is currently negative at $-0.02 billion.

Based on FMP financials and quantitative analysis

AORT Key Highlights

Market Cap of $1.36B indicates a strong valuation within the medical device sector.

• P/E Ratio of 32.6 suggests investors are paying a premium for Artivion's earnings, reflecting growth expectations.
• Gross Margin of 63.6% demonstrates efficient cost management and strong pricing power.
• Free Cash Flow of $-0.02B indicates the company is currently investing heavily in growth initiatives.
• Beta of 1.64 suggests the stock is more volatile than the market, potentially offering higher returns but also higher risk.

Who Are AORT's Competitors?

AORT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AORT's Key Strengths?

Diverse product portfolio catering to various surgical needs.

• Established brand reputation and strong customer relationships.
• Proprietary technologies and patented products.
• Global distribution network and market presence.

What Are AORT's Weaknesses?

Reliance on regulatory approvals for new products.

• Exposure to product liability claims and recalls.
• Fluctuating free cash flow and profitability.
• High beta indicating greater stock volatility.

What Could Drive AORT Stock Higher?

Potential regulatory approvals for new product lines, expanding market reach.

• Increasing adoption of minimally invasive surgical techniques driving demand for Artivion's products.
• Strategic partnerships and collaborations enhancing product development and distribution capabilities.

What Are the Key Risks for AORT?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Rich valuation — a P/E of 32.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Product liability claims and recalls impacting brand reputation and financial performance.
• Economic downturns affecting healthcare spending and demand for elective surgical procedures.
• Intense competition from established medical device companies.
• Reimbursement challenges and pricing pressures affecting profitability.

What Are the Growth Opportunities for AORT?

• Expansion of Aortic Stent Graft Portfolio: Artivion has the opportunity to capitalize on the growing market for aortic stent grafts, driven by the increasing prevalence of aortic aneurysms and the shift towards minimally invasive endovascular repair techniques. The global aortic stent graft market is projected to reach $3 billion by 2028. Artivion's E-vita THORACIC 3G and E-nya stent graft systems position the company to capture a significant share of this market. The timeline for realizing this growth opportunity is ongoing, with continuous product development and market penetration efforts.
• Strategic Acquisitions and Partnerships: Artivion can pursue strategic acquisitions and partnerships to expand its product portfolio, geographic reach, and technological capabilities. By acquiring complementary businesses or partnering with innovative companies, Artivion can accelerate its growth trajectory and enhance its competitive position. The medical device industry is characterized by consolidation, with larger companies acquiring smaller players to gain access to new technologies and markets. The timeline for potential acquisitions and partnerships is ongoing, with Artivion actively evaluating opportunities.
• Increased Adoption of BioGlue Surgical Adhesive: BioGlue, Artivion's surgical adhesive, has the potential for increased adoption in cardiac, vascular, and pulmonary procedures. The global surgical adhesives market is projected to reach $2 billion by 2027. BioGlue's unique properties and clinical benefits position it as a preferred choice for surgeons seeking reliable and effective tissue sealing. Artivion can drive adoption through targeted marketing efforts, clinical studies, and expansion into new geographic markets. The timeline for increased BioGlue adoption is ongoing, with continuous efforts to promote its use.
• Penetration of Emerging Markets: Artivion has the opportunity to expand its presence in emerging markets, where healthcare spending is increasing and access to advanced medical technologies is improving. Countries like China, India, and Brazil represent significant growth opportunities for medical device companies. Artivion can establish distribution networks, build relationships with local healthcare providers, and adapt its product offerings to meet the specific needs of these markets. The timeline for emerging market penetration is ongoing, with a long-term focus on building sustainable growth.
• Development of Next-Generation Heart Valves: Artivion's On-X prosthetic heart valves represent a key growth area, with the potential for developing next-generation valves that offer improved durability, hemodynamics, and patient outcomes. The global heart valve market is projected to reach $10 billion by 2028. Artivion can invest in research and development to create innovative valve designs and technologies that address unmet clinical needs. The timeline for developing next-generation heart valves is ongoing, with a focus on long-term innovation and market leadership.

What Are AORT's Competitive Advantages?

• Proprietary Technologies: Artivion's BioGlue surgical adhesive and On-X prosthetic heart valves are protected by patents and trade secrets, providing a competitive advantage.
• Established Brand Reputation: Artivion has built a strong reputation for quality and reliability among surgeons and healthcare providers.
• Extensive Product Portfolio: Artivion offers a comprehensive range of medical devices and implantable tissues, catering to a wide range of surgical needs.
• Global Distribution Network: Artivion has established a global distribution network, enabling it to reach customers in key markets worldwide.

What Does AORT Do?

Founded in 1984 and headquartered in Kennesaw, Georgia, Artivion Inc. has evolved into a global medical device company focused on developing, manufacturing, and distributing innovative solutions for cardiac and vascular surgeons. Originally known as CryoLife, Inc., the company rebranded as Artivion Inc. in January 2022 to reflect its expanded product portfolio and strategic vision. Artivion's core offerings include BioGlue, a surgical adhesive used in cardiac and vascular procedures; PhotoFix, a bovine pericardial patch; and the E-vita line of aortic stent grafts. The company's product range extends to synthetic vascular grafts, PerClot absorbable hemostat, cardiac laser therapy products, and On-X prosthetic heart valves. Artivion serves a diverse customer base, including physicians, hospitals, and healthcare facilities, providing them with essential tools for treating a wide range of cardiovascular and thoracic conditions. Artivion's commitment to innovation and quality has established it as a key player in the medical device industry, with a focus on improving patient outcomes through advanced surgical solutions.

What Products and Services Does AORT Offer?

• Manufactures and distributes medical devices and implantable human tissues.
• Offers BioGlue, a surgical adhesive used in cardiac, vascular, and pulmonary procedures.
• Provides PhotoFix, a bovine pericardial patch for tissue repair.
• Develops and markets the E-vita line of aortic stent grafts for treating aortic diseases.
• Offers synthetic vascular grafts for open aortic and peripheral vascular surgeries.
• Provides PerClot, an absorbable powdered hemostat for surgical procedures.
• Manufactures and distributes On-X prosthetic heart valves.
• Offers cardiac preservation services and vascular preservation services.

How Does AORT Make Money?

• Artivion generates revenue through the sale of its medical devices and implantable tissues to hospitals, physicians, and healthcare facilities.
• The company's business model relies on innovation and product development to create differentiated solutions for cardiac and vascular surgeons.
• Artivion utilizes a direct sales force and distribution network to reach its customers globally.
• The company also generates revenue through pyrolytic carbon coating services for medical device manufacturers.

What Industry Does AORT Operate In?

Artivion operates in the medical device industry, a sector characterized by continuous innovation, stringent regulatory oversight, and increasing demand for advanced healthcare solutions. Artivion competes with established players and emerging companies, focusing on cardiac and vascular devices. Key trends include the shift towards minimally invasive procedures, the integration of digital technologies, and the growing importance of personalized medicine.

Who Are AORT's Key Customers?

• Physicians specializing in cardiac, vascular, thoracic, and general surgery.
• Hospitals and healthcare facilities performing surgical procedures.
• Medical device manufacturers utilizing Artivion's pyrolytic carbon coating services.
• Patients requiring surgical interventions for cardiac and vascular diseases.

Wall Street analysts project Artivion Inc. revenue of about $486.2M for fiscal 2026, with EPS near $0.08. The estimate reflects 6 contributing analysts.

Artivion Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.10 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for Artivion Inc. stands at 2.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.3%, showing how much profit it generates from its asset base. AORT trades at a trailing price-to-earnings ratio of 32.63, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.1%, the inverse of the P/E and a quick read on earnings relative to price.

Artivion Inc. (AORT) Valuation Context

Valued at $1.36B, AORT is classified as a small-cap stock. Relative to its peer group, AORT's quantitative score of 33/100 is below the peer average of 69/100.

AORT Revenue & Earnings Trend

In Q2 2026, AORT generated $125.8M in top-line revenue, marking a sequential increase of 8.1%. The company recorded a net loss of $13.5M, with diluted EPS of $-0.28. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, AORT averaged $-0.02 in diluted EPS.

Company Profile

Artivion Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Kennesaw, US. The company is led by CEO James Patrick Mackin. AORT has traded publicly since 1993.

AORT Financials

AORT Latest News

AORT Analyst Consensus

AORT MoonshotScore

AORT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources